Chemistry:MSP-1014

From HandWiki

MSP-1014 is a serotonergic psychedelic which is under development for the treatment of major depressive disorder, other depressive disorders, and anxiety disorders.[1][2][3][4][5][6]

It is a prodrug of psilocin similarly to psilocybin, and hence acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor.[1][3][4][6][7] The animal pharmacodynamics and pharmacokinetics of MSP-1014 have been studied,[3][6] demonstrating a shorter plasma half-life compared to psilocybin.

The drug is under development by Mindset Pharma and Otsuka America Pharmaceutical.[1][2][3][4] As of January 2024, it is in phase 2 clinical trials for major depressive disorder and is in the preclinical stage of development for anxiety disorders and other depressive disorders.[1][2][4] The chemical structure of MSP-1014 does not yet seem to have been disclosed.[1][2][3] However, Mindset Pharma patented psilocin derivatives and prodrugs in 2022.[8]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 "MSP 1014". 9 January 2024. https://adisinsight.springer.com/drugs/800064119. 
  2. ↑ 2.0 2.1 2.2 2.3 "Delving into the Latest Updates on MSP-1014 with Synapse". 26 October 2024. https://synapse.patsnap.com/drug/1aa26df90be04ed9a1f2da26d8a22bce. 
  3. ↑ 3.0 3.1 3.2 3.3 3.4 "Modification of natural tryptamines for the treatment of neuropsychiatric diseases". J Psychopharmacol 39 (12): 1338–1350. December 2025. doi:10.1177/02698811251368362. PMID 41045211. "Another prodrug reported to be a psilocybin-like conjugate, MSP-1014, is under clinical development by Otsuka America Pharmaceutical and Mindset Pharma for the treatment of MDD (Arbe, 2023). While the structure of MSP-1014 has not been disclosed, various long- chain fatty acid ester prodrugs of psilocin have been reported (e.g., see psilocin-O-linoleate in Table 2 (Slassi and Araujo, 2023)). In preclinical studies, SC injection of MSP-1014 in rodents produced a higher HTR with reduced effects on locomotor activity and core body temperature, compared to psilocybin at the same dose, suggesting MSP-1014 may be a better-tolerated prodrug than psilocybin (Araujo et al., 2022).". 
  4. ↑ 4.0 4.1 4.2 4.3 "Mindset Pharma Receives Approval for Phase II Clinical Trial Evaluating MSP-1014 for the Treatment of Major Depressive Disorder". 22 June 2023. https://www.biospace.com/mindset-pharma-receives-approval-for-phase-ii-clinical-trial-evaluating-msp-1014-for-the-treatment-of-major-depressive-disorder. "MSP-1014 is a novel and patent-protected prodrug of psilocin, the active metabolite of psilocybin. MSP-1014 is anticipated to exert similar efficacy to psilocybin in improving symptoms of depression. Preclinical studies comparing MSP-1014 to psilocybin suggest that the tolerability of MSP-1014 may be superior to psilocybin." 
  5. ↑ Mindset Pharma (14 November 2022). "Mindset Pharma Presents Poster at Neuroscience 2022 Highlighting Preclinical Data on MSP-1014, its Psilocybin-like Lead Drug Candidate". GlobeNewswire News Room (Press release). Retrieved 29 October 2024.
  6. ↑ 6.0 6.1 6.2 Araujo JA, Higgins GA, de Lannoy IA, Dean I, Atkinson J, Lanthier J, Slassi M. (2022 November 13). 147.05 / JJ5 - The preclinical safety, behavioural and pharmacokinetics properties of MSP-1014, a novel prodrug of psilocin. Neuroscience 2022. https://www.abstractsonline.com/pp8/#!/10619/presentation/70912
  7. ↑ "Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy". CNS Spectrums 28 (4): 416–426. July 2022. doi:10.1017/S1092852922000888. PMID 35811423. 
  8. ↑ Slassi A, Araujo J, "Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders", US patent 2022/0289774, issued 7 March 2023



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:MSP-1014&oldid=4433204"